Cargando…
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
BACKGROUND: Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed to evaluate the MS Centers behavior regarding HBV screening and prophylaxis in a large cohort...
Autores principales: | Buonomo, Antonio Riccardo, Viceconte, Giulio, Calabrese, Massimiliano, De Luca, Giovanna, Tomassini, Valentina, Cavalla, Paola, Maniscalco, Giorgia Teresa, Ferraro, Diana, Nociti, Viviana, Radaelli, Marta, Buscarinu, Maria Chiara, Paolicelli, Damiano, Gajofatto, Alberto, Annovazzi, Pietro, Pinardi, Federica, Di Filippo, Massimiliano, Cordioli, Cinzia, Zappulo, Emanuela, Scotto, Riccardo, Gentile, Ivan, Spiezia, Antonio Luca, Petruzzo, Martina, De Angelis, Marcello, Brescia Morra, Vincenzo, Solaro, Claudio, Gasperini, Claudio, Cocco, Eleonora, Moccia, Marcello, Lanzillo, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119877/ https://www.ncbi.nlm.nih.gov/pubmed/35165767 http://dx.doi.org/10.1007/s00415-022-11009-x |
Ejemplares similares
-
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2022) -
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022) -
“Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study
por: Calabrese, Massimiliano, et al.
Publicado: (2019) -
COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak
por: Buonomo, Antonio, et al.
Publicado: (2020) -
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)